

Tabular Curriculum Vitae – Bokemeyer, Carsten

PERSONAL INFORMATION

Surname, first name, degree: Bokemeyer, Carsten, Professor Dr. med., M.D.
Place/Date of birth: Braunschweig, Germany / 15.09.1962
Official Address: Department of Internal Medicine II (Oncology, Hematology, BMT, Pneumology)
University Medical Center Hamburg Eppendorf
Martinistrasse 52
20246 Hamburg, Germany
E-mail: c.bokemeyer@uke.de
Phone: +49 40 7410 53962

CURRENT POSITION

Director of the Department of Internal Medicine II, University Hospital-Hamburg-Eppendorf
Senior Director University Cancer Center Hamburg

WORK EXPERIENCE / MAJOR POSITIONS

Since 2017 **Director and Spokesman** University Cancer Center Hamburg
2007-2010 **Founding Member** of the University Cancer Center Hamburg
Since 2004 **Director** of Division of Oncology, Hematology, Bone Marrow Transplantation
with Section Pneumology, Hamburg University
1995-2004 **Senior Physician** Department of Internal Medicine
Division of Hematology / Oncology / Immunology / Rheumatology
University of Tübingen Medical Center, Tübingen, Germany
1989-1995 **Assistant Physician** University of Hannover Medical School, Department of
Hematology / Oncology, Hannover, Germany

EDUCATION AND TRAINING

2004 **Appointed Professor of Medicine** UKE, Hamburg
2001 **Visiting Professorship** Memorial Sloan-Kettering Cancer Center, New York,
Department of Medical Oncology
2000 **Associate Professor of Medicine** at Tübingen University
1996 **“Habilitation”** (Postdoctoral lecturing qualification), Department of Internal
Medicine, University of Hannover Medical School
1991 **Thesis** (Dr. med.), University of Hannover Medical School, Hannover
Study of Medicine:
1982 - 1989 Hannover Medical School, Hannover, Germany
1986 - 1987 DAAD scholarship, Memorial Sloan-Kettering Cancer Center, New York,
Department of Leukemia Cell Biology

SELECTED HONOURS AND AWARDS

2000 **Deutscher Krebspreis**; National Award of the German Cancer Society
2000 **Award for Experimental Urological Research**, German Society of Urology
2006 **Scientific Award for Medical Oncology (AIO)**
2006 **Anita- und Cuno-Wieland-Preis**, Honorary Award of the University of
Heidelberg
2014 **ESMO-Award**, Award of the European Society of Medical Oncology
2018 **Wilhelm Warner Award** Excellent Achievements in Cancer Research

PROFESSIONAL RESPONSIBILITIES

2023	Congress president of the annual congress of the German, Austrian and Swiss Societies of Hematology and Oncology, Hamburg 2023
Since 2019	Member of the Committee 3 National Decade against Cancer
Since 2019	Chair of the DKH network of German Oncology Centres of Excellence
2016-17	President of the German Society of Hematology and Medical Oncology (DGHO)
2014	Congress president of the annual congress of the German, Austrian and Swiss Societies of Hematology and Oncology, Hamburg Oktober 2014 (DGHO)
Since 2014	President of the Northwest German Society of Internal Medicine
2005-2014	Member Executive Board of the German Cancer Society (DKG)
2002-2009	Advisory board member of the German Society of Hematology and Oncology
2002-2010	Chairman of the ESMO Examination Committee for Medical Oncology
Since 1995	Experience in GCP-conform conduction of clinical studies as participant and investigator

Author / coauthor of more than 900 original publications / reviews (2023)
H-Index 105 (excluding self citations), Research Gate Index 55

Selected Papers:

Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM).

Janning M, Süptitz J, Albers-Leischner C, Delpy P, Tufman A, Velthaus-Rusik JL, Reck M, Jung A, Kauffmann-Guerrero D, Bonzheim I, Brändlein S, Hummel HD, Wiesweg M, Schildhaus HU, Stratmann JA, Sebastian M, Alt J, Buth J, Esposito I, Berger J, Tögel L, Saalfeld FC, Wermke M, Merkelbach-Bruse S, Hillmer AM, Klauschen F, **Bokemeyer C**, Buettner R, Wolf J, Loges S; National Network Genomic Medicine Lung Cancer (nNGM). Ann Oncol. 2022 Jun;33(6):602-615.

Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy'.

Westphalen BC, **Bokemeyer C**, Büttner R, Fröhling S, Gaidzik VI, Glimm H, Hacker UT, Heinemann V, Illert AL, Keilholz U, Kindler T, Kirschner M, Schilling B, Siveke JT, Schroeder T, Tischler V, Wagner S, Weichert W, Zips D, Loges S; Working Group Molecular Diagnostics and Therapy. Eur J Cancer. 2020 Aug;135:1-7

Multi-omic based **molecular** profiling of advanced cancer identifies treatable targets and improves survival in individual patients.

Samsen A, von der Heyde S, **Bokemeyer C**, David KA, Flath B, Graap M, Grebenstein B, Heflik L, Hollburg W, Layer P, von Leitner E, Overkamp F, Saeger W, Schneider S, von Seydewitz CU, Stang A, Stein A, Zornig C, Juhl H. Oncotarget. 2018 Oct 5;9(78):34794-34809

Indirect Treatment Comparison of **Larotrectinib** versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers.

Garcia-Foncillas J, **Bokemeyer C**, Italiano A, Keating K, Paracha N, Fellous M, Marian M, Fillbrunn M, Gao W, Ayyagari R, Lassen U. Cancers (Basel). 2022 Mar 31;14(7):1793

Estimating Long-Term Survival Outcomes for Tumor-Agnostic Therapies: **Larotrectinib** Case Study.

Briggs A, Paracha N, Rosettie K, Upton A, **Bokemeyer C**, Lassen U, Sullivan SD. *Oncology*. 2022;100(2):124-130

Survival Outcomes of Patients With Tropomyosin Receptor Kinase Fusion-Positive Cancer Receiving **Larotrectinib** Versus Standard of Care: A Matching-Adjusted Indirect Comparison Using Real-World Data.

Bokemeyer C, Paracha N, Lassen U, Italiano A, Sullivan SD, Marian M, Brega N, Garcia-Foncillas J. *JCO Precis Oncol*. 2023 Jan;7:e2200436

Impact of Disease Evolution on Efficacy Outcomes From **Larotrectinib** in Patients With Locally Advanced or Metastatic Tropomyosin Receptor Kinase Fusion-Positive Solid Tumors.

Bokemeyer C, Vassal G, Italiano A, De La Cuesta E, Hiemeyer F, Fellous M, Marian M. *JCO Precis Oncol*. 2021 Sep 13;5:PO.21.00089